Biotech stock Neurocrine surges more than 22% after FDA approves first drug for movement disorder
April 12, 2017 at 10:05 AM EDT
Neurocrine says the FDA has approved Ingrezza, the only drug for treatment of adults with tardive dyskinesia.
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.